TY - JOUR
T1 - Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer
T2 - Therapeutic implications
AU - Pneumaticos, Spyros G.
AU - Christofides, Anthos
AU - Gkioka, Eliona
AU - Kalogeropoulos, Theodoros
AU - Msaouel, Pavlos
AU - Koutsilieris, Michael
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/12
Y1 - 2013/12
N2 - Introduction: Osteoprotegerin (OPG) acts as a soluble decoy receptor for the bone marrow stroma cell-derived and osteoblast-derived receptor activator of nuclear factor-kB ligand (RANKL), thus regulating the RANK-mediated osteoclastogenesis and osteoclast-mediated bone resorption at the metastatic niche of cancer in skeleton. Areas covered: This article discusses the 'key' role of OPG expression during the early events of cancer cell invasion into the bone matrix and the subsequent events underlying the formation of osteoblastic metastasis, a unique event observed in human prostate cancer biology. Expert opinion: Understanding the cellular and molecular events implicated in bone metastasis can facilitate designing new therapeutic strategies for targeting early and/or late events in the metastasis processes. The RANKL/RANK/OPG pathway is a key regulator of pathological bone metabolism in metastatic sites. Targeted manipulation of these molecules may provide sustainable antitumor responses.
AB - Introduction: Osteoprotegerin (OPG) acts as a soluble decoy receptor for the bone marrow stroma cell-derived and osteoblast-derived receptor activator of nuclear factor-kB ligand (RANKL), thus regulating the RANK-mediated osteoclastogenesis and osteoclast-mediated bone resorption at the metastatic niche of cancer in skeleton. Areas covered: This article discusses the 'key' role of OPG expression during the early events of cancer cell invasion into the bone matrix and the subsequent events underlying the formation of osteoblastic metastasis, a unique event observed in human prostate cancer biology. Expert opinion: Understanding the cellular and molecular events implicated in bone metastasis can facilitate designing new therapeutic strategies for targeting early and/or late events in the metastasis processes. The RANKL/RANK/OPG pathway is a key regulator of pathological bone metabolism in metastatic sites. Targeted manipulation of these molecules may provide sustainable antitumor responses.
KW - Bone microenvironment
KW - OPG
KW - Osteoblastic metastasis
KW - Osteoclastogenesis
KW - RANK
KW - RANKL
UR - http://www.scopus.com/inward/record.url?scp=84887936245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887936245&partnerID=8YFLogxK
U2 - 10.1517/14728222.2013.834889
DO - 10.1517/14728222.2013.834889
M3 - Review article
C2 - 24024908
AN - SCOPUS:84887936245
SN - 1472-8222
VL - 17
SP - 1395
EP - 1403
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 12
ER -